Resolution of Mild Ganciclovir-Resistant Cytomegalovirus Disease with Reduced-Dose Cidofovir and CMV-Hyperimmune Globulin

Table 2

Characteristics of ganciclovir-resistant cytomegalovirus and treatment.

Patient number	Time from 1st PCR to GCV-R diagnosis (days)	UL97 mutation site	PCR at time of GCV-R diagnosis (copies)	SCr/GFR/CrCl at time of GCV-R diagnosis	Total VGC exposure prior to GCV-R diagnosis (days)	CMV disease category	Total number of cidofovir infusions	GFR at end of treatment
1	82	A594V	1538	1.8/54/65	260	Syndrome, suspected GI invasion	7	45
2	162	A594V	2257	1.9/39/66	252	Syndrome	2	45
3	101	L595W	2777	1.6/61/73	186	Syndrome	5	61
4	65	L595S	1818	1.6/61/69	169	Syndrome	17	60

CrCl: creatinine clearance (mL/min); GCV-R: ganciclovir-resistant; GFR: glomerular filtration rate (mL/min/1.73²); GI: gastrointestinal; PCR: polymerase chain reaction; SCr: serum creatinine (mg/dL); VGC: valganciclovir.